Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P De Backer

Showing results (41-50 of 157) with videos related to

Pageof 16
Sort By:
European Journal of Pharmacology|March 17, 1999
Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cellsF Fierens, P M Vanderheyden, J P De Backer, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|September 4, 2001
Simultaneous quantitation of ephedrines in urine by gas chromatography-nitrogen-phosphorus detection for doping control purposesP Van Eenoo, F T Delbeke, K Roels, et al.
Journal of Neurochemistry|November 1, 1989
[3H]GBR 12935 binding to dopamine uptake sites in the human brainJ De Keyser, J P De Backer, G Ebinger, et al.
Neurochemistry International|February 14, 1998
The venom of Conus pennaceus inhibits the binding of [3H]neuropeptide Y by direct interaction with the radioligandB Diallo, P M Vanderheyden, J P De Backer, et al.
Archives Internationales De Pharmacodynamie Et De Therapie|October 1, 1982
Protein binding and pharmacokinetics of sulfamerazine in neonatal and young lambsP De Backer, F M Belpaire, M G Bogaert, et al.
Veterinary Microbiology|November 7, 2008
Evaluation of orally administered valacyclovir in experimentally EHV1-infected poniesB Garré, A Gryspeerdt, S Croubels, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 1, 1995
Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatumJ De Keyser, J P De Backer, N Wilczak, et al.
Brain Research|September 4, 1989
Coupling of D1 dopamine receptors to the guanine nucleotide binding protein Gs is deficient in Huntington's diseaseJ De Keyser, J P De Backer, G Ebinger, et al.
European Journal of Pharmacology|July 8, 1999
Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist bindingF L Fierens, P M Vanderheyden, J P De Backer, et al.
Current Medicinal Chemistry. Cardiovascular and Hematological Agents|August 24, 2004
AT1 receptor antagonistsI Verheijen, P M L Vanderheyden, J P De Backer, et al.
Pageof 16

Showing results (41-50 of 157) with videos related to

Sort By:
Pageof 16
European Journal of Pharmacology|March 17, 1999
Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cellsF Fierens, P M Vanderheyden, J P De Backer, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|September 4, 2001
Simultaneous quantitation of ephedrines in urine by gas chromatography-nitrogen-phosphorus detection for doping control purposesP Van Eenoo, F T Delbeke, K Roels, et al.
Journal of Neurochemistry|November 1, 1989
[3H]GBR 12935 binding to dopamine uptake sites in the human brainJ De Keyser, J P De Backer, G Ebinger, et al.
Neurochemistry International|February 14, 1998
The venom of Conus pennaceus inhibits the binding of [3H]neuropeptide Y by direct interaction with the radioligandB Diallo, P M Vanderheyden, J P De Backer, et al.
Archives Internationales De Pharmacodynamie Et De Therapie|October 1, 1982
Protein binding and pharmacokinetics of sulfamerazine in neonatal and young lambsP De Backer, F M Belpaire, M G Bogaert, et al.
Veterinary Microbiology|November 7, 2008
Evaluation of orally administered valacyclovir in experimentally EHV1-infected poniesB Garré, A Gryspeerdt, S Croubels, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 1, 1995
Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatumJ De Keyser, J P De Backer, N Wilczak, et al.
Brain Research|September 4, 1989
Coupling of D1 dopamine receptors to the guanine nucleotide binding protein Gs is deficient in Huntington's diseaseJ De Keyser, J P De Backer, G Ebinger, et al.
European Journal of Pharmacology|July 8, 1999
Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist bindingF L Fierens, P M Vanderheyden, J P De Backer, et al.
Current Medicinal Chemistry. Cardiovascular and Hematological Agents|August 24, 2004
AT1 receptor antagonistsI Verheijen, P M L Vanderheyden, J P De Backer, et al.
Pageof 16